GlaxoSmithKline Pharmaceuticals Limited
GLAXO
Rang in Aktien
#3633
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Aktienkurs
$27.56
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$4.67B
Veränderung (1 Tag)
-2.65%
Veränderung (1 Jahr)
-11.79%
Land
IN
Handel GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
Kategorie
Healthcare
EPS für GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
EPS zum June 2026 TTM: $0.70
Laut den aktuellen Finanzberichten und dem Aktienkurs von GlaxoSmithKline Pharmaceuticals Limited beträgt das aktuelle EPS des Unternehmens (TTM) $0.70. Am Ende des Jahres 2024 betrug das EPS $0.42 ein Rückgang im Vergleich zu dem EPS von 2023, das $0.44 betrug.
EPS-Verlauf von GlaxoSmithKline Pharmaceuticals Limited von 2004 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.70 | 8.72% |
| 2025 | $0.64 | 53.29% |
| 2024 | $0.42 | -4.31% |
| 2023 | $0.44 | 55.78% |
| 2022 | $0.28 | 20.93% |
| 2021 | $0.23 | 217.40% |
| 2020 | $0.07 | -80.72% |
| 2019 | $0.38 | 19.09% |
| 2018 | $0.32 | 3.69% |
| 2017 | $0.31 | -8.50% |
| 2016 | $0.34 | -7.07% |
| 2015 | $0.36 | -0.91% |
| 2013 | $0.36 | -39.74% |
| 2012 | $0.60 | 26.71% |
| 2011 | $0.48 | -35.63% |
| 2010 | $0.74 | 14.81% |
| 2009 | $0.64 | -10.33% |
| 2008 | $0.72 | -12.43% |
| 2007 | $0.82 | 11.92% |
| 2006 | $0.73 | 11.91% |
| 2005 | $0.66 | 47.32% |
| 2004 | $0.45 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $29.89 | 4,195.77% |
US
|
|
| $6.60 | 848.55% |
US
|
|
| $3.55 | 410.20% |
US
|
|
| $1.26 | 81.09% |
US
|
|
| $20.39 | 2,830.30% |
CH
|
